Looking back on my posts on this thread, a third dimension needs to be touched on..., that of implications of results.
If the variability factor of CR , when tested, were to remain constant, then trial numbers and elimination of cancer correlate hand in hand exponentially.
Well done to Joseph Sprano (chief investigator) and his team.
Recruiting, based on phase 1 results, must now be even more encouraging for both parties involved.
Luck to those who hold long.
PTX Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
